DeepMed Research

Caspofungin

Generic Name: Caspofungin

Brand Names: Cancidas, Cancidas (previously Caspofungin MSD)

Drug Type: Small Molecule

Chemical Formula: C_₅₂H_₈₈N_₁₀O_₁₅

CAS Number: 162808-62-0

Unique Ingredient Identifier: F0XDI6ZL63

Background: Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.

Indication: For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Associated Conditions: Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections

Clinical Trials

Pharmacokinetics of Caspofungin

Completed

Conditions: Critical Illness
Fungal Infection
Septic Shock

Interventions: Drug: Caspofungin

First Posted Date: 2018-01-16

Last Posted Date: 2023-11-24

Lead Sponsor: Medical University of Lublin

Target Recruit Count: 33

Registration Number: NCT03399032

Locations: 🇵🇱
II Department of Anesthesia and Intensive Care, Medical University of Lublin, Lublin, Poland

A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

Phase 4

Terminated

Conditions: Hematologic Neoplasms

Interventions: Drug: Caspofungin
Drug: Itraconazole

First Posted Date: 2016-09-09

Last Posted Date: 2019-05-06

Lead Sponsor: Xian-Janssen Pharmaceutical Ltd.

Target Recruit Count: 61

Registration Number: NCT02895529

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

Phase 1

Withdrawn

Conditions: Pulmonary Aspergillosis - Invasive
Acute Myeloid Leukemia

Interventions: Drug: F901318
Drug: Caspofungin

First Posted Date: 2016-08-04

Last Posted Date: 2018-02-15

Lead Sponsor: F2G Biotech GmbH

Registration Number: NCT02856178

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Phase 2

Completed

Conditions: Fungal Infection
Fungemia
Invasive Candidiasis
Candidemia
Mycoses

Interventions: Drug: CD101
Drug: Caspofungin
Drug: intravenous placebo
Drug: Fluconazole
Drug: oral placebo

First Posted Date: 2016-04-12

Last Posted Date: 2020-12-08

Lead Sponsor: Cidara Therapeutics Inc.

Target Recruit Count: 207

Registration Number: NCT02734862

Locations: 🇪🇸
University Hospital La Paz, Madrid, Spain
🇧🇪
UCL Saint-LUC, Brussels, Belgium
🇺🇸
Virginia Tech, Carillion School of Medicine, Roanoke, Virginia, United States

and more 60 locations

Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

Not Applicable

Conditions: Pneumocystis Pneumonia

Interventions: Drug: Sulfanilamides
Drug: caspofungin
Drug: corticosteroids

First Posted Date: 2015-11-13

Last Posted Date: 2020-03-13

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 60

Registration Number: NCT02603575

Locations: 🇨🇳
Beijing Chao Yang Hospital, Beijing, China

Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients

Not Applicable

Completed

Conditions: Shock

Interventions: Drug: Caspofungin

First Posted Date: 2015-11-04

Last Posted Date: 2019-06-14

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 50

Registration Number: NCT02596984

Locations: 🇫🇷
CHU de CLERMONT-FERRAND, Clermont-ferrand, France
🇫🇷
Hôpital Saint-Louis, Paris, France
🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France

Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit

Not Applicable

Conditions: Invasive Fungal Infection

Interventions: Drug: Caspofungin

First Posted Date: 2015-07-28

Last Posted Date: 2015-07-28

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 40

Registration Number: NCT02510053

Optimal Dosage of Caspofungin in Critically Ill Patients

Phase 4

Completed

Conditions: Suspected Invasive Candidiasis
Critically Ill

Interventions: Drug: Caspofungin

First Posted Date: 2013-11-25

Last Posted Date: 2015-10-30

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 20

Registration Number: NCT01994096

Locations: 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

Phase 4

Completed

Conditions: Bacterial Infections and Mycoses
Liver Disease

Interventions: Drug: Caspofungin 70 mg

First Posted Date: 2013-10-24

Last Posted Date: 2019-02-15

Lead Sponsor: Erasme University Hospital

Target Recruit Count: 20

Registration Number: NCT01968395

Locations: 🇧🇪
Erasme University Hospital, Brussels, Belgium

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Phase 2

Terminated

Conditions: Candidiasis, Invasive

Interventions: Drug: Caspofungin
Drug: Amphotericin B Deoxycholate

First Posted Date: 2013-09-18

Last Posted Date: 2019-11-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 51

Registration Number: NCT01945281

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy